Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$74M
- −74.3% YoY · −16.5% QoQ
- EPS (diluted)
- −$0.77
- −57.1% YoY · −28.3% QoQ
Source: XBRL data from the Olema Pharmaceuticals, Inc. (OLMA) Q3 2026 10-Q on SEC EDGAR. USD.
Olema Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales
- Net loss $73.6M vs $42.2M YoY, operating margin not disclosed
- R&D largest expense $67.6M, up 69% YoY, driven by OPERA trials and OP-3136
- Cash, equivalents and securities $413.8M; operating cash use $139.0M vs $108.4M
- Runway through mid-2028; OPERA-01 results expected Q1 2027, funding and macroeconomic risks remain
Risk Factors
- Newly triggered debt risk: Fourth Amendment added Olema Oncology International Limited as secured guarantor on July 1, 2026
- Most material financial update: outstanding Credit Facility liability reached $3.0 million as of September 30, 2026
- Regulatory risk: FDA may issue a Refusal to File if palazestrant NDA deficiencies preclude substantive review
- Operational risk: OPERA-02 Phase 3 trial combines palazestrant with ribociclib, exposing development to combination-therapy dependencies
- Competitive risk: palazestrant faces approved competitors including ORSERDU, ETCAMAH, and Inluriyo
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Olema Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.